Nebulizer

Global Respiratory Care Devices Industry to Cross $36.96B by 2027 - Trends, Opportunities, Impact of COVID-19, Company Analysis, and More - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 24, 2022
Medical Devices, Health, CDC, Physician, Population, Philips, Masimo, Death, Global, Urbanization, Hospital, Mouth, WHO, Chronic obstructive pulmonary disease, Prevalence, PAP, Center, Asthma, COVID-19, Sleep apnea, Industry, World, Smoking, Centers for Disease Control and Prevention timeline, Johnson & Johnson, Degenerative disease, Tobacco smoking, Adoption, Nose, Medtronic, ResMed, COPD, World Health Organization, Ageing, Patient, Air pollution, Medical tourism, Humidifier, BD (company), Research, Incidence, Obstructive sleep apnea, Nebulizer, Animal, Pharmaceutical industry, Invacare, Growth

The Global Respiratory Care Devices Market is expected to reach US$ 36.96 billion by 2027.

Key Points: 
  • The Global Respiratory Care Devices Market is expected to reach US$ 36.96 billion by 2027.
  • It expresses the emphasis on respiratory care in the background of a pandemic; the respiratory care devices market has shown healthy growth.
  • Based on product type, the global respiratory care devices industry is segmented into monitoring devices, therapeutic devices, diagnostic devices, and consumables & accessories.
  • The therapeutic devices segment has accounted for a significant share of the global respiratory care devices industry.

Doctors for Disaster Preparedness Recommends COVID Medical Kit

Retrieved on: 
Wednesday, January 12, 2022
People, Quercetin, Patient, Cyproheptadine, Montelukast, Triglyceride, D3, Nebulizer, Dutasteride, Tablet, DDP, Disaster, Death, Fenofibrate, Melatonin, Colchicine, Cholesterol, Zinc, Transport, Physician, COVID, Dietary supplement, Pharmaceutical industry

TUCSON, Ariz., Jan 12, 2022 /PRNewswire/ -- In its January newsletter ,Doctors for Disaster Preparednesssuggests that all households should have a COVID medical kit, which is also a general medical kit.

Key Points: 
  • TUCSON, Ariz., Jan 12, 2022 /PRNewswire/ -- In its January newsletter ,Doctors for Disaster Preparednesssuggests that all households should have a COVID medical kit, which is also a general medical kit.
  • With supply chain disruptions, essential items may be unobtainable when needed, and professional medical services may be inaccessible.
  • The kit should include a blood pressure monitor, a clinical thermometer tested to be sure it works, a pulse oximeter, and possibly a nebulizer.
  • Doctors for Disaster Preparedness is a group of scientists (including physicians) founded in 1984, which provides information to help save lives in the event of natural or man-made disasters.

Celltrion announces positive results for its cocktail therapy candidates including neutralisation data against Omicron variant

Retrieved on: 
Monday, January 3, 2022
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, EMA, National, Medicine, Tolerability, Committee for Medicinal Products for Human Use, CHMP, COVID-19, Celltrion, US, Omicron, Nebulizer, European Medicines Agency, Clinical trial, European Directive on Traditional Herbal Medicinal Products, Pharmacokinetics, Gamma, Lung, Marketing, Mucus, Severe acute respiratory syndrome coronavirus 2, Partnership, AES, NIH, Inflammation, Terminology, Infection, Viral load, Patient, EC, Committee, Forward-looking statement, EU, RBD, Medical imaging, Vaccine, Pharmaceutical industry, Audit, Safety, Delta, Celltrion Healthcare, regdanvimab (CT-P59), CT-P63, nebulised formulation, CELLTRION HEALTHCARE, REGDANVIMAB (CT-P59), CT-P63, NEBULISED FORMULATION

Celltrion anticipates results of the SARS-CoV-2 Omicron variant assays and animal model studies by the end of the first quarter this year.

Key Points: 
  • Celltrion anticipates results of the SARS-CoV-2 Omicron variant assays and animal model studies by the end of the first quarter this year.
  • CT-P63 has previously been demonstrated to have neutralising activity against the most common variants, including the Alpha, Beta, Gamma and Delta variants.
  • The positive results demonstrate the potential of our cocktail therapy to retain neutralising ability against the Omicron variant said Dr. HoUng Kim, Ph.D., Head of Medical and Marketing Division at Celltrion Healthcare.
  • We are confident that our antibody platform including Regkirona and CT-P63 will provide significant benefit for patients with COVID-19.

DGAP-News: APEIRON Biologics commences clinical COVID-19 trial with inhaled APN01

Retrieved on: 
Tuesday, October 12, 2021
Inflammation, Pharmacokinetics, Jazz Pharmaceuticals, Infection, National, Department, Liver, SARS, VUMC, COVID-19, Kidney disease, ACE2, Cell, Heart, Nebulizer, Mads, Vanderbilt University Medical Center, APN01, Safety, Cancer, Inhalation, Neuroblastoma, World Health Organization, Lung, Pharmacology, PAH, Medical school, Chronic obstructive pulmonary disease, Degenerative disease, COPD, Blood pressure, Severe acute respiratory syndrome coronavirus 2, CMSO, CEO, Kidney, SADS, Therapy, Cell membrane, RAAS, NIH, Patient, Disease, Clinical trial, Government, World, University College, Oxford, Medical University of Vienna, Biomarker, Pulmonary hypertension, Pharmaceutical industry, Vaccine, APN01 (alunacedase alfa), APEIRON Biologics AG, APN01 (ALUNACEDASE ALFA), APEIRON BIOLOGICS AG

Romana Gugenberger PhD, CMSO of APEIRON Biologics AG, explains: "The start of this company sponsored trial for APN01 is a vital next step in our development approach.

Key Points: 
  • Romana Gugenberger PhD, CMSO of APEIRON Biologics AG, explains: "The start of this company sponsored trial for APN01 is a vital next step in our development approach.
  • Peter Llewellyn-Davies, CEO of APEIRON Biologics AG, adds: "We desperately need an effective treatment for COVID-19 and an inhaled application is an important strategic milestone for APEIRON.
  • This is the third clinical trial dedicated to the multi-armed initiative of developing APN01 into vital therapy options in COVID-19.
  • APEIRON Biologics' projects and technologies are based on a strong patent portfolio and partnerships with leading pharmaceutical companies and academic institutions.

Insights on the Pulmonary/ Respiratory Drug Delivery Global Market to 2027 - Featuring 3M, Cipla and Omron Among Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 27, 2021
Health, Pharmaceutical, Health sciences, Health care, Aerosols, Medical equipment, Nebulizer, Respiratory therapy, Health

The "Pulmonary/ Respiratory Drug Delivery - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Pulmonary/ Respiratory Drug Delivery - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • The U.S. Market is Estimated at $12.5 Billion, While China is Forecast to Grow at 4.8% CAGR
    The Pulmonary/ Respiratory Drug Delivery market in the U.S. is estimated at US$12.5 Billion in the year 2020.
  • In the global Nebulizer segment, USA, Canada, Japan, China and Europe will drive the 5.4% CAGR estimated for this segment.
  • Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$6.9 Billion by the year 2027.

Global Respiratory Care Devices Markets, 2015-2020 & 2021-2026: Chronic Obstructive Pulmonary Disease, Asthma, Sleep Apnea, Infectious Disease - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 13, 2021
Medical devices, Health, Medicine, Health care, Clinical medicine, Respiratory therapy, Medical equipment, Dosage forms, Intensive care medicine, Mechanical ventilation, Nebulizer, Positive airway pressure, Humidifier, Respiratory therapist

The global respiratory care devices market exhibited strong growth during 2015-2020.

Key Points: 
  • The global respiratory care devices market exhibited strong growth during 2015-2020.
  • Looking forward, the global respiratory care devices market to grow at a CAGR of around 11% during the forecast period (2021-2026).
  • Nebulizers, inhalers, positive airway pressure (PAP) devices, spirometers, humidifiers, etc., are some of the most commonly used respiratory care devices.
  • What is the structure of the global respiratory care devices industry and who are the key players?

$1.67 Billion Nebulizers Market - Global Industry Trends, Share, Size, Growth, Opportunity and Forecasts, 2015-2020 & 2021-2026 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 7, 2021
Pharmaceutical, Health, Other Health, Health sciences, Medical equipment, Respiratory therapy, Health care, Dosage forms, Aerosols, Health, Nebulizer

The "Nebulizers Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Nebulizers Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.
  • The global nebulizers market reached a value of US$ 1.67 Billion in 2020.
  • Nebulizers are devices that are used by patients suffering from respiratory diseases to administer the medication directly into the lungs.
  • Key Questions Answered in This Report:
    How has the global nebulizers market performed so far and how will it perform in the coming years?

United Therapeutics Announces FDA Acceptance of Tyvaso DPI™ New Drug Application For Priority Review

Retrieved on: 
Wednesday, June 16, 2021
Health sciences, Health care, Dosage forms, Respiratory therapy, Health, MannKind Corporation, Nebulizer, United Therapeutics, Dots per inch, Inhaler, DPI, Daytona Prototype International

If approved, Tyvaso DPI is expected to provide a more convenient method of administration compared with traditional nebulized Tyvaso therapy.

Key Points: 
  • If approved, Tyvaso DPI is expected to provide a more convenient method of administration compared with traditional nebulized Tyvaso therapy.
  • United Therapeutics is developing Tyvaso DPI under a collaboration and license agreement with MannKind Corporation (Nasdaq: MNKD).
  • United Therapeutics and MannKind are also developing BluHale, a Bluetooth-connected accessory for the Tyvaso DPI inhaler with a companion mobile application intended to help the patient track information about inhaler use.
  • Between-subject variability for both AUC0-5h and Cmax was approximately 50% less for Tyvaso DPI compared to Tyvaso Inhalation Solution, suggesting a more precise dosing profile for Tyvaso DPI relative to nebulized Tyvaso.

Encore Healthcare Announces Staggering Results in New Nexus TeleRespiratory Care Pilot Using Data to Predict when Oxygen/Nebulizer Patients Need Non-Invasive Ventilation (NIV) Before Hospitalizations Happen

Retrieved on: 
Friday, June 11, 2021
Medicine, Health sciences, Clinical medicine, Respiratory therapy, Medical equipment, Dosage forms, Aerosols, Nebulizer, Oxygen, Oxygen therapy, Chronic obstructive pulmonary disease, Respiratory therapist

LIVINGSTON, Tenn., June 11, 2021 /PRNewswire/ --Encore Healthcare announces staggering results from their new oxygen and nebulizer management Nexus TeleRespiratory Care model.

Key Points: 
  • LIVINGSTON, Tenn., June 11, 2021 /PRNewswire/ --Encore Healthcare announces staggering results from their new oxygen and nebulizer management Nexus TeleRespiratory Care model.
  • In the initial pilot with a national HME provider Encore identified 12.5% of patients on oxygen/nebulizers needed additional services including medications, NIV and High Frequency Chest Wall Oscillation (HFCWO).
  • These results are an example of how data can drive better patient outcomes and revenue to HME providers at the same time.
  • The Nexus platform aligns HME respiratory providers across traditional boundaries while increasing provider productivity and clinical outcomes with their Ventilator/High-Risk COPD patients.

Verona Pharma and Nuance Pharma Announce $219 Million Strategic Collaboration to Develop and Commercialize Ensifentrine in Greater China

Retrieved on: 
Thursday, June 10, 2021
Branches of biology, Medical specialties, Anatomy, Cystic fibrosis, Lung disorders, Channelopathies, Respiratory therapy, Mucus, Nebulizer, Denufosol

Ensifentrine also activates the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), which is beneficial in reducing mucous viscosity and improving mucociliary clearance.

Key Points: 
  • Ensifentrine also activates the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), which is beneficial in reducing mucous viscosity and improving mucociliary clearance.
  • Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs.
  • The Company is evaluating nebulized ensifentrine in its Phase 3 clinical program ENHANCE (Ensifentrine as a Novel inHAled Nebulized COPD thErapy) for COPD maintenance treatment.
  • Since its inception in 2014, Nuance Pharma has assembled a portfolio of promising clinical-stage drug candidates for respiratory, pain and iron deficiency anemia.